Table 2.
Experimentally verified CTL epitopes restricted by protective HLA alleles (used in Figure 1A).
| Epitope | Protein | Positiona | HLA | Predicted IC50 (nM)b |
|---|---|---|---|---|
| GRGKPGIYRF | NS3 | 466–475 | HLA-B*27 | 1195 |
| KGGRKPARLIVFPDL | NS5B | 151–165 | HLA-B*27 | 484 |
| ARHTPVNSW | NS5B | 400–408 | HLA-B*27 | 1447 |
| ARMILMTHF | NS5B | 421–429 | HLA-B*27 | 129 |
| GRAAICGKY | NS5B | 516–524 | HLA-B*27 | 122 |
| GRWVPGAAY | P7 | 34–42 | HLA-B*27 | 100 |
| NTRPPLGNWF | E2 | 158–167 | HLA-B*57 | 241 |
| LTTSQTLLF | NS4B | 90–98 | HLA-B*57 | 306 |
| KSKKTPMGF | NS5B | 209–217 | HLA-B*57 | 121 |
| LGVPPLRAWR | NS5B | 492–501 | HLA-B*57 | 157 |
aPosition with respect to the HCV reference strain H77.
bFor peptides longer than 9 amino acids, the nine-mer with the best binding affinity is shown in bold italics, and this is the binding affinity reported in the last column.